Fritextsökning
Innehållstyper
-
“Access to capital increases when there’s an exit”
It remains a tough environment for biotech companies seeking financing – but there is good reason to hope for improvement ahead. That’s the view of Okee William...
-
Acne medication may be the solution when hair starts falling out
A treatment originally developed for acne has shown remarkable Phase III results in a completely different area: male-pattern hair loss.
-
Shaping the Future of Metrology – Live in Your Region
Insights into our event series.
-
Experience innovations of the future
ZEISS QUALITY INNOVATIONS WORLDWIDE event in Oberkochen, Germany, January 20-21, 2026.
-
ZEISS Smartzoom 100 for Inspection Efficiency
Catch up on our free webinar.
-
Could an overly burdensome QMS be the organization’s own doing?
Although the above statement is intentionally somewhat provocative, it does hold a degree of truth. Organizations that are generally negative toward regulations...
-
Astra Zeneca pauses multi-million investment in the UK
Astra Zeneca has paused a planned investment worth $270 million. It is the latest pharmaceutical company to pull back on its commitments in the UK.
-
GU Ventures AB
-
Heart Monitoring in Breast Cancer – Essential or Excessive?
Trastuzumab and related drugs have transformed breast cancer treatment and dramatically improved survival rates. But the close cardiac monitoring required durin...
-
FDA launches investigation into gene therapy following child death
The U.S. Food and Drug Administration (FDA) has initiated a safety investigation into Takeda’s Adzynma after reports that a child has died during treatment. The...
-
Southern Swedish company Aqilion develops drug for eosinophilic esophagitis
When Aqilion began developing a drug for eosinophilic esophagitis, the molecule was classified as an orphan drug. But the prevalence of the disease now appears ...
-
New findings on the diseases that crushed Napoleon’s army
As if cold, starvation, and typhus weren’t enough. New research reveals that Napoleon’s defeated army also suffered from paratyphoid fever and relapsing fever d...
-
Explore the possibilities of the new ZEISS METROTOM 800 320 kV
Free ZEISS webinar July 10, 9:00-9:45 AM and 5:00-5:45 PM.
-
Shaping regulatory complexity into strategic clarity
As AI continues to reshape healthcare, clear guidance on health data use is more critical than ever. Building on the success of the AI Act e-tool and the Data A...
-
BMS and venture capital giant form new company
The American pharmaceutical company Bristol Myers Squibb, together with the venture capital firm Bain Capital, is forming a new biotech company. The company wil...
-
One System, Three Contrasting Techniques
ZEISS Axioscan 7 clinical - your digital slide scanner for diagnostics and clinical research.
-
Webinar: Can AI replace humans in pharmacovigilance?
The webinar will explore how AI can transform pharmacovigilance by enhancing efficiency, reducing errors, and addressing challenges such as software costs, data security, and regulatory gaps....
-
DBB ventiler: Snabbare installationer och färre skarvar
Spirax Sarco Safebloc är en lösning med en unik platsbesparande design som innebär snabbare installation och färre skarvar. Spirax
-
Sneak Peek of ZEISS Metrology Expert Tips Season 2
The second season of the video series starts in January 2026, but you can discover more about the highlights of Season 2 now.
-
Cancer dominerar svenska läkemedelsprövningar – här är andra heta områden
För första gången finns en nationell och samlad bild av de läkemedelsprövningar som pågår i Sverige. Den visar att onkologi är klart dominerande, men också att ...
-
Mercodia AB
-
Speed meets precision for high-density components
ZEISS METROTOM 800 320 kV.
-
USA och Storbritannien i nytt avtal – nolltullar för läkemedel
USA och Storbritannien har enats om ett handelsavtal som avskaffar amerikanska tullar på brittiska läkemedel och medicintekniska produkter. I utbyte lovar Storb...
-
Vaccine project targeting congenital infection scrapped in late-stage trial – “Clearly disappointed”
Hope for the first vaccine against the world’s most common congenital infection has taken a serious hit